The purpose of this trial is to characterize the safety and toxicity of DKN-01 by determining
a maximum-tolerated dose and associated dose limiting toxicity. To evaluate the
pharmacodynamic response in patients with cancer. To characterize the pharmacokinetic
parameters of DKN-01 in cancer patients who are intolerant to standard/approved therapies.